Cepheid has announced the launch of its next-generation Xpert Flu test for the GeneXpert System, a CE IVD-marked product offering on-demand STAT testing for triage, outbreaks, emergencies and high-risk patient management.
In any healthcare environment, rapid, accurate diagnosis of influenza is vital for effective clinical management and infection control. Cepheid’s Xpert Flu is the only molecular diagnostic test capable of providing on-demand results in just over an hour.
With faster turnaround times for improved workflows, plus wider coverage, it enables real-time determination of Flu A and Flu B infection, as well as the identification of 2009 H1N1, maximising medical decision-making. This leads to improved isolation and infection control measures, enhancing patient flow and bed use, and reducing the pressure on hospital resources.
Xpert Flu is a key component of Cepheid’s Winter Care Bundle – comprising of the Xpert Flu, Xpert SA Nasal Complete, Xpert C.difficile and Xpert Norovirus rapid tests – an essential tool kit in the battle against highly-transmissible infections, helping to reduce the potential for preventable ward closures.